These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 16648503

  • 1. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A.
    J Clin Oncol; 2006 May 01; 24(13):2038-43. PubMed ID: 16648503
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS.
    J Clin Oncol; 2005 May 20; 23(15):3488-94. PubMed ID: 15908658
    [Abstract] [Full Text] [Related]

  • 3. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, Tamura T, Saijo N.
    Clin Cancer Res; 2005 Aug 01; 11(15):5534-8. PubMed ID: 16061870
    [Abstract] [Full Text] [Related]

  • 4. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr 01; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 5. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct 01; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M, West Japan Thoracic Oncology Group 9902.
    J Clin Oncol; 2006 Nov 20; 24(33):5247-52. PubMed ID: 17114657
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 20; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 20; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 9. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR.
    J Clin Oncol; 2009 May 20; 27(15):2530-5. PubMed ID: 19349543
    [Abstract] [Full Text] [Related]

  • 10. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T, Japan Clinical Oncology Group.
    Lancet Oncol; 2014 Jan 20; 15(1):106-13. PubMed ID: 24309370
    [Abstract] [Full Text] [Related]

  • 11. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
    Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M.
    Ann Oncol; 2010 Sep 20; 21(9):1810-1816. PubMed ID: 20231298
    [Abstract] [Full Text] [Related]

  • 12. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 20; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

  • 13. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY.
    BMC Cancer; 2016 Aug 26; 16(1):690. PubMed ID: 27566413
    [Abstract] [Full Text] [Related]

  • 14. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 26; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 15. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug 26; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 16. Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
    Jiang L, Yang KH, Mi DH, Liu YL, Tian JH, Ma B, Tan JY, Bai ZG.
    Clin Lung Cancer; 2007 Sep 26; 8(8):497-501. PubMed ID: 17922975
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 26; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
    William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS.
    Cancer; 2010 May 15; 116(10):2409-15. PubMed ID: 20225329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.